Notice Concerning Changes in Subsidiary and Equity-Method Affiliate
Filed with TSE · · 3 pages · English
Company name: NIPRO CORPORATION Name of representative: Tsuyoshi Yamazaki, Representative Board Director President and CEO (Securities code: 8086; Prime Market) Inquiries: Mitsugu Sato, CSO Corporate Planning Headquarters (Telephone: +81-6-6310-6804) Notice Concerning Changes in Subsidiary and Equity-Method Affiliate NIPRO CORPORATION (the “Company”) hereby announces that, at the Board of Director
Earlier from NIPRO
- Announcement of Investment by Development Bank of Japan Inc. in a U.S. Subsidiary of NIPRO
- Notice Concerning Change in Depreciation Method
- Announcement of Spryte Medical, a US Affiliate of NIPRO, First Participants Enrolled in the “INSYTE” US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment
- Notice Concerning the Establishment of the Record Date for the Year-End Dividend
- Announcement of Expansion of Commercial Collaboration Between Gentuity LLC, a US Affiliate of NIPRO, and GE HealthCare
Later from NIPRO
- Notice Concerning Expected Recording of Extraordinary Income from Sale of Investment Securities
- NIPRO Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
- [Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)
- Notice Regarding Conversion Results and Redemption of Euro-Yen Denominated Convertible Bonds Due 2026
Follow NIPRO into a list and get an email when it puts out news.
Follow NIPRO